Company Overview of Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry in the United States. Its lead product candidate, omadacycline, is a tetracycline-derived and broad-spectrum antibiotic developed in oral tablet and intravenous formulations for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other serious community-acquired bacterial infections. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III trials planne...
75 Kneeland Street
Boston, MA 02111
Key Executives for Paratek Pharmaceuticals, Inc.
Chairman of the Board and Chief Executive Officer
Total Annual Compensation: $128.5K
President, Chief Medical Officer and Director
Total Annual Compensation: $488.8K
Chief Financial Officer and Secretary
Total Annual Compensation: $10.4K
Vice President of Research and Development
Total Annual Compensation: $226.0K
Compensation as of Fiscal Year 2014.
Paratek Pharmaceuticals, Inc. Key Developments
Paratek Pharmaceuticals, Inc. Expands Leadership Team with Two New Hires
Oct 1 15
Paratek Pharmaceuticals, Inc. has expanded its senior leadership team with two new hires. The company announced that Regina Paglia has joined as Senior Vice President, Human Resources and Stephen Villano, M.D. has joined as Vice President, Clinical and Medical Affairs. Ms. Paglia will be based in Paratek's Boston headquarters. Dr. Villano will be based out of the company's Philadelphia office. Paratek is a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon tetracycline chemistry. It's lead compound, omadacycline, is in Phase 3 development. Ms. Paglia previously held the position of Senior Vice President, Human Resources at Myriant Corporation, where she led initiatives aimed at creating an optimal corporate culture for employee recruitment and retention, such as reward systems, benefits, professional development and other policies. In this capacity, Ms. Paglia also designed and introduced a branded Mission and Core Values initiative for the newly appointed CEO to define organizational direction and enhance employee engagement. Prior to her experience at Myriant, Ms. Paglia served as Vice President, Human Resources for Mascoma Corporation. In this role, she focused on strategies to optimize corporate culture and organizational effectiveness, led the CEO search and was responsible for facilitating a successful transition. Ms. Paglia was also Senior Vice President, Human Resources at Sepracor Pharmaceutical, Inc., now Sunovion Pharmaceuticals, where she led HR Organizational initiatives to scale-up for commercialization. With more than 20 years experience in antiviral and anti-infective research, Dr. Villano previously served as Vice President, Clinical Research and Development at ViroPharma, Inc, adding Business Development to his responsibilities in 2011. In this role, Dr. Villano directed R&D activities for the company's anti-infective programs, and was responsible for medical oversight of clinical studies. He was also responsible for the identification and review of early compounds with potential in niche markets or orphan drugs. Prior to his position at ViroPharma, Dr. Villano was Medical Director, Virology, Medical Science & Development at Dupont Pharmaceuticals Company, where he focused on the development of the antiretroviral medication efavirenz.
Paratek Pharmaceuticals, Inc. Presents at Ladenburg Thalmann 2015 Healthcare Conference, Sep-29-2015 10:30 AM
Sep 2 15
Paratek Pharmaceuticals, Inc. Presents at Ladenburg Thalmann 2015 Healthcare Conference, Sep-29-2015 10:30 AM. Venue: Sofitel Hotel, New York, New York, United States. Speakers: Evan Loh, President, Chief Medical Officer and Director.
Paratek Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015
Aug 5 15
Paratek Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported loss from operations of $15,679,000 against $1,881,000 a year ago. Net loss attributable to common stockholders was $15,699,000 or $0.96 per basic and diluted share against $3,007,000 or $41.79 per basic and diluted share a year ago.
For the six months, the company reported loss from operations of $26,312,000 against $2,812,000 a year ago. Net loss attributable to common stockholders was $26,332,000 or $1.71 per basic and diluted share against $4,420,000 or $63.32 per basic and diluted share a year ago.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|